Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Kohsuke IsomotoKoji HarataniHidetoshi HayashiShigeki ShimizuShuta TomidaTakashi NiwaToshihide YokoyamaYasushi FukudaYasutaka ChibaRyoji KatoJunko TanizakiKaoru TanakaMasayuki TakedaTakashi OguraTadashi IshidaAkihiko ItoKazuhiko NakagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
EGFR-TKI treatment was associated with changes in the TME of EGFR-mutated NSCLC, and such changes may provide clues for optimization of subsequent PD-1 inhibitor treatment.